US FDA Permits AliveCor's AI Mobile ECG To Measure QTc In COVID-19 Patients

24 Mar 2020

AliveCor wins US FDA permission to use its mobile ECG to detect heart problems caused by drugs to treat COVID-19 patients.

Heart disorder and atrial fibrillation ecg as a coronary cardiac attack with irregular and normal organ rhythm as a chest discomfort disease concept in a 3D illustration style.

AliveCor Inc., which markets a six-lead consumer electrocardiography (ECG) device called KardiaMobile 6L for at-home use and in clinical settings to detect heart arrythmias, announced yesterday that the US Food and Drug Administration permitted an expanded use of the device to detect prolonged heartbeats caused by medications used to treat COVID-19.

The announcement follows a new guidance issued by the FDA on 20 March that allows manufacturers of patient-monitoring devices to...